BCAA Detection and Analysis
What to Measure
| Analyte | Why it matters | Typical range in medium |
|---|---|---|
| Leucine | mTORC1 signalling; ketogenic carbon | 0.4–0.8 mM |
| Isoleucine | Mixed ketogenic and anaplerotic | 0.4–0.8 mM |
| Valine | Anaplerotic | 0.4–0.8 mM |
| α-Ketoisocaproate (KIC) | Leucine transamination product | Low micromolar |
| α-Keto-β-methylvalerate (KMV) | Isoleucine product | Low micromolar |
| α-Ketoisovalerate (KIV) | Valine product | Low micromolar |
Important distinction. The BCAAs and their keto acids are two halves of a reversible reaction. BCAA concentration alone reflects supply and uptake as much as catabolism; the keto acid concentration reflects the transamination equilibrium. Only measuring both, and ideally the flux between them, distinguishes transfer from catabolism.
Part 1 — Methods
| Method | Analytes | Sensitivity | Note |
|---|---|---|---|
| LC-MS/MS with derivatisation (AQC, dansyl, FMOC) | Amino acids | High | Derivatisation improves retention and ionisation |
| LC-MS/MS without derivatisation, HILIC or ion-pairing | Amino acids | Moderate | Simpler; matrix effects |
| LC-MS of keto acids with derivatisation (PFBHA, aniline) | BCKAs | High | Keto acids are poorly ionised without derivatisation |
| GC-MS | Amino acids and keto acids | High | Requires derivatisation; good precision |
| Enzymatic assays | Leucine or total BCAA | Low specificity | Suitable for screening only |
| NMR | Abundant metabolites | Moderate | No derivatisation; lower sensitivity |
Readout note. The keto acids are the harder measurement and the more informative one. A BCAA panel without keto acids describes supply; a panel with keto acids describes where the transamination equilibrium sits, and that is what a catabolism claim needs.
Part 2 — Sampling
| Step | Requirement | Consequence if omitted |
|---|---|---|
| Medium sampling | Fixed volume and timepoint | Uptake cannot be computed |
| Immediate quench | Cold, or acidified | Continued transamination and catabolism |
| Cell separation | Brief spin, cold | Leakage from damaged cells |
| Storage | −80 °C; keto acids are less stable than amino acids | Decarboxylation |
| Derivatisation timing | Consistent across samples | Batch effects |
| Internal standards | Isotope-labelled leucine, isoleucine, valine, and keto acid analogues | Recovery and matrix correction |
Caveat on keto acid stability. BCKAs decarboxylate and are volatile in acidic solution. Storage at −80 °C, avoidance of strong acid, and derivative formation soon after extraction reduce the loss. A keto acid value that drifts between runs is usually a handling problem rather than a biological one.
Part 3 — Normalisation and Interpretation
| Basis | Appropriate when | Caveat |
|---|---|---|
| Concentration in medium | Uptake or release | Requires volume and time |
| Per cell number | Comparing conditions | Counting at low numbers |
| Per mg protein | Routine | Protein changes with treatment |
| Ratio of BCAA to BCKA | Catabolic equilibrium | Both measurements must be from the same sample |
Important distinction. In culture, the BCAA concentration is usually several-fold above plasma. A fall in medium BCAA therefore reports a large absolute consumption against a large baseline, and a "50% depletion" in culture may be a smaller change than the same percentage in plasma. Reporting absolute concentrations, not only percentages, keeps the comparison honest.
Part 4 — What the Data Can Support
| Claim | Requires | Not sufficient |
|---|---|---|
| "BCAA consumption increased" | Medium depletion with volume, time and cell number | Transporter expression |
| "Catabolism increased" | BCKA production or ¹³C-leucine oxidation | BCAA depletion |
| "Transamination increased" | BCAA to BCKA ratio shift | BCAA concentration |
| "mTORC1 was activated by leucine" | Dose–response plus a leucine-insensitive control | Correlation with proliferation |
| "BCAA contribute to anaplerosis" | ¹³C labelling into succinate or malate from valine | Total BCAA consumption |
Part 5 — Common Failures
- • Total BCAA reported as one number.
- • Keto acids not measured, so catabolism is inferred rather than measured.
- • BCAA depletion reported as catabolism, when uptake or dilution also changed.
- • No internal standards, so recovery is unknown.
- • Keto acid samples stored in acid and shipped, so values fall.
- • Culture concentrations treated as physiological.
- • Leucine effects attributed to catabolism, when the mTORC1 route explains them.
- • Normalisation to protein in treatments that change protein content.
Part 6 — Where This Article Connects
This is the analytical companion to the BCAA article, which covers BCAT, BCKDH and the three carbon fates. It connects to the glutaminolysis article through α-ketoglutarate, which BCAT consumes, and to the nucleotide article through the anaplerotic contribution of valine and isoleucine.
If you need BCAA and BCKA measured in the same sample with isotope standards, we can scope the analysis with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
BCAA and BCKA concentrations, recovery and stability vary by matrix, derivatisation and storage. Method validation is required for each analyte class.
A BCAA concentration does not establish catabolic flux, and a keto acid change does not establish the direction of net transamination without flux data.
Scientific interpretation and experimental design
- • Three amino acids, three fates. Report separately.
- • Keto acids carry the information. Measure them.
- • Keto acids are unstable. Cold, neutral, frozen.
- • Absolute values, not only percentages.
- • Uptake is not catabolism.
- • Signalling is not catabolism.
Selected references for further reading
- • Neinast M, Murashige D, Arany Z. Branched chain amino acids. Annual Review of Physiology. 2019;81:139–164.
- • Newgard CB, et al. A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance. Cell Metabolism. 2009;9:311–326.
- • White PJ, et al. The BCKDH kinase and phosphatase integrate BCAA and lipid metabolism via regulation of ATP-citrate lyase. Cell Metabolism. 2018;27:1281–1293.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »